3275 : CR-OXYCODONE FOR LONG-TERM NON-MALIGNANT PAIN TREATMENT: DOSING, EFFICACY, AND SAFETY

Author(s): 
Richards, Patricia; Backonja, Misha-Miroslav; Portenoy, Russell; Gleeland, Charles; Farrar, John; Yang, Kaity; Friedman, Michael
Text: 
Poster
Research Based
OBJECTIVE: Evaluate dosing, efficacy, and safety of long-term treatment with oral con trolled-release (CR)-oxycodone (OxyContin*, oxycodone HCI controlled-release tablets) for moderate to severe non-malignant pain.
METHODS: Eligible subjects completed previous one of five comparative CR-oxycodone trial for non-malignant pain and required continued opioid analgesia for moderate to severe pain. Dosing, Brief Pain Inventory (BPI), and adverse events were collected at baseline and every 3 months, up to approximately 36 months. Repeated measures ANCOVA models were used.
RESULTS: Two hundred nineteen subjects out of 233 enrolled were evaluable for efficacy. Mean (SE) daily dose of CR-oxycodone was 52.5± 2.6 mg and mean dosing duration was 541.5± 25.0 days. During titration (from baseline to Month 3), dose increased at 3.3± 0.4mg/month. After titration, dosing remained relatively stable, increasing 1.4± 0.2 mg/month during months 3-12 and 0.3± 0.1 mg/month during months 12-36 (ANCOVA). BPI worst pain scores improved from baseline (mean=7.1) through Month 33 (mean=5.8) (paired I-test, pSUMMARY AND CONCLUSIONS: Long-term use of CR-oxycodone in patients with non-malignant pain appears to be effective in maintaining analgesia without significant increase in daily dose after titration. Adverse events seen were consistent with opioid treatment.
Topic: Evidence-based Medicine